Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Qulipta
Pharma
AbbVie eyes Qulipta expansion after menstrual migraine win
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta.
Fraiser Kansteiner
Sep 10, 2026 11:05am
AbbVie's Ubrelvy fares well warding off migraines in study
Aug 29, 2024 11:58am
Pfizer's Vydura gets NICE nod to treat episodic migraine attacks
Sep 13, 2023 7:01pm
Docs very willing to use AbbVie's Qulipta in chronic migraine
Apr 25, 2023 12:46pm
AbbVie's Qulipta gains approval to prevent chronic migraines
Apr 18, 2023 3:20pm
FDA signs off on Pfizer's Zavypret, a nasal spray for migraine
Mar 10, 2023 10:53am
